Acadian Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-17,167
| Closed | – | – | 2001 |
|
|
2025
Q4 | $0 | Sell |
17,167
-1,467,986
| -99% | -$199K | ﹤0.01% | 1946 |
|
|
2025
Q3 | $186K | Sell |
1,485,153
-478,988
| -24% | -$65.7K | ﹤0.01% | 1413 |
|
|
2025
Q2 | $459K | Sell |
1,964,141
-254,074
| -11% | -$67.8K | ﹤0.01% | 1157 |
|
|
2025
Q1 | $424K | Buy |
2,218,215
+1,707,999
| +335% | +$884K | ﹤0.01% | 1110 |
|
|
2024
Q4 | $269K | Buy |
+510,216
| New | +$372K | ﹤0.01% | 1202 |
|
|
2023
Q3 | – | Sell |
-358,010
| Closed | -$329K | – | 1622 |
|
|
2023
Q2 | $329K | Buy |
358,010
+47,085
| +15% | +$56.1K | ﹤0.01% | 1158 |
|
|
2023
Q1 | $332K | Sell |
310,925
-214,569
| -41% | -$332K | ﹤0.01% | 1143 |
|
|
2022
Q4 | $760K | Buy |
525,494
+413,926
| +371% | +$670K | ﹤0.01% | 914 |
|
|
2022
Q3 | $116K | Buy |
111,568
+97,980
| +721% | +$180K | ﹤0.01% | 1330 |
|
|
2022
Q2 | $23K | Sell |
13,588
-30,620
| -69% | -$52.6K | ﹤0.01% | 1600 |
|
|
2022
Q1 | $91K | Buy |
+44,208
| New | +$119K | ﹤0.01% | 1379 |
|
|
2021
Q1 | – | Sell |
-301,408
| Closed | -$1.63M | – | 2035 |
|
|
2020
Q4 | $1.63M | Buy |
+301,408
| New | +$1.64M | 0.01% | 827 |
|
|
2019
Q3 | – | Sell |
-42,517
| Closed | -$170K | – | 1864 |
|
|
2019
Q2 | $170K | Buy |
42,517
+23,143
| +119% | +$94.4K | ﹤0.01% | 1263 |
|
|
2019
Q1 | $83K | Sell |
19,374
-18,704
| -49% | -$87.1K | ﹤0.01% | 1566 |
|
|
2018
Q4 | $219K | Buy |
+38,078
| New | +$281K | ﹤0.01% | 1093 |
|
|
2018
Q2 | – | Sell |
-27,508
| Closed | -$309K | – | 1673 |
|
|
2018
Q1 | $309K | Buy |
27,508
+11,397
| +71% | +$99.7K | ﹤0.01% | 965 |
|
|
2017
Q4 | $108K | Sell |
16,111
-9,011
| -36% | -$69.6K | ﹤0.01% | 1076 |
|
|
2017
Q3 | $206K | Buy |
+25,122
| New | +$157K | ﹤0.01% | 912 |
|
Other funds holding ADAP
Acadian Asset Management's ADAP Position: Q1 2026 in Review
Acadian Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 17,167 shares.
Acadian Asset Management first reported a position in ADAP in Q3 2017 and held it in 18 quarters. The position peaked at $1.63M in Q4 2020. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.
- Acadian Asset Management reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
- Acadian Asset Management sold 17,167 Adaptimmune Therapeutics shares in Q1 2026.
- Acadian Asset Management first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 18 quarters.
- Acadian Asset Management's Adaptimmune Therapeutics position peaked at $1.63M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.